ЛУНДЕБЕРГ Томас (SE),ПАРАЗАССИ Тицьяна (IT),ПИТТАЛУГА Эуджениа (IT),БРУНЕЛЛИ Роберто (IT)
申请号：
RU2015115398
公开号：
RU2015115398A
申请日:
2013.11.06
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A pharmaceutical composition comprising N-acetyl-L-cysteine (NAC) alone or together with (2) selenium in the form of selenomethionine and / or (3) melatonin and / or their physiologically acceptable salts for use in IVF (in vitro fertilization) ) treatment of a mammal. 2. The pharmaceutical composition according to claim 1, characterized in that a dose of 50-150 mg / kg of NAC body weight is administered intravenously once a day for 1-3 days, or a dose of 30-45 mg / kg of NAC body weight is administered once a day orally, or alternatively, 600 mg of NAC is administered three times a day orally for three consecutive days a week, followed by four days without administration of a drug with a total duration of three months or more before IVF treatment. 3. The pharmaceutical composition according to claim 2, containing N-acetyl-L-cysteine for use in IVF treatment of a mammal, characterized in that a dose of 50-150 mg / kg of body weight is administered intravenously once a day for 1-3 days or orally administered a dose of 30-45 mg / kg body weight once a day. 4. The pharmaceutical composition according to claim 1, containing N-acetyl-L-cysteine, for use in mammalian IVF, characterized in that the composition is intended for intravenous administration of a dose of N-acetyl-L-cysteine from 50 to 150 mg / kg body weight , once a day for 1-3 days in conjunction with IVF treatment. 5. The pharmaceutical composition of claim 1, comprising a mammalian N-acetyl-L-cysteine, characterized in that a dose of 600 mg of N-acetyl-L-cysteine is administered orally for three consecutive days a week, followed by four days without drug administration, in three months or more before IVF treatment. 6. A pharmaceutical composition comprising N-acetyl-L-cysteine for1. Фармацевтическая композиция, содержащая N-ацетил-L-цистеин (NAC) сам по себе или вместе с (2) селеном в форме селенометионина и/или (3) мелатонином и/или их физиологически приемлемыми солями для использования в ЭКО(экстракорпо
